Cover Image

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System

Esketamine was approved for the treatment of treatment-resistant depression in 2019. After the approval of esketamine, numerous concerns have been raised regarding its long-term safety and tolerability. A previous systematic pharmacovigilance study on esketamine-related adverse events (AEs) was publ...

Full description

Saved in:

Bibliographic Details
Main Authors:	Haoning Guo (Author), Bin Wang (Author), Shuying Yuan (Author), Silin Wu (Author), Jing Liu (Author), Miaoquan He (Author), Jisheng Wang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
by: Haoning Guo, et al.
Published: (2022)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024)

Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System
by: Huqun Li, et al.
Published: (2024)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022)

Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2024)

Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database
by: Ruixue Liu, et al.
Published: (2024)

Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system
by: Jun Shen, et al.
Published: (2024)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
by: Yue He, et al.
Published: (2024)

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system
by: Huqun Li, et al.
Published: (2023)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
by: Feifei Wang, et al.
Published: (2023)

A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system
by: Yiwen Wang, et al.
Published: (2024)

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
by: Xianglin Pan, et al.
Published: (2024)

A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system
by: Kaixuan Wang, et al.
Published: (2024)

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
by: Bin Zhao, et al.
Published: (2024)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
by: Zhihong Fang, et al.
Published: (2023)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Yamin Shu, et al.
Published: (2022)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
by: Feifei Wang, et al.
Published: (2022)

A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS)
by: Jie Zhou, et al.
Published: (2024)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024)

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
by: Dehua Zhao, et al.
Published: (2023)

Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
by: Wenqiang Kong, et al.
Published: (2023)

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system
by: Wei Wei, et al.
Published: (2024)

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
by: Wenting Zhang, et al.
Published: (2024)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
by: Yankun Liang, et al.
Published: (2023)

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
by: Ming-Tao Wen, et al.
Published: (2024)

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023
by: Jinger Lin, et al.
Published: (2024)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
by: Si Su, et al.
Published: (2023)

A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database
by: Huanying Xu, et al.
Published: (2024)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
by: Yiwen Bao, et al.
Published: (2024)

A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
by: Weizhen He, et al.
Published: (2024)

Serious Neurological Adverse Events of Ceftriaxone
by: Clémence Lacroix, et al.
Published: (2021)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022)

Vonoprazan-associated infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System
by: Mengling Ouyang, et al.
Published: (2024)

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
by: Michele Fusaroli, et al.
Published: (2021)

Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system
by: Kaibin Niu, et al.
Published: (2024)

Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System
by: Giuseppe Cicala, et al.
Published: (2024)

Reporting of adverse events following immunizations in Ghana - Using disproportionality analysis reporting ratios
by: Daniel N. A. Ankrah, et al.
Published: (2018)

Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis
by: Aidou Jiang, et al.
Published: (2024)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
by: Pan Ma, et al.
Published: (2022)